2019-04-10

Camurus’ rights issue oversubscribed

Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of the launch and marketing of Buvidal in Europe and Australia.

Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of the launch and marketing of Buvidal in Europe and Australia. Buvidal is Camurus’ first approved drug for the treatment of opioid dependence.

The rights issue was guaranteed by Sandberg Development.

Read more at Camurus’ website: https://www.camurus.com/pressreleases/